Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Peter Teuber"'
Autor:
Thomas D. Boyer, Lorenzo Rossaro, Victor Araya, Florence Wong, Hugo E. Vargas, Peter Teuber, R. T. Frederick, S. C. Pappas, Khurram Jamil, K.R. Reddy, S. Escalante, Arun J. Sanyal
Publikováno v:
Alimentary Pharmacology & Therapeutics
Summary Background The goal of hepatorenal syndrome type 1 (HRS‐1) treatment is to improve renal function. Terlipressin, a synthetic vasopressin analogue, is a systemic vasoconstrictor used for the treatment of HRS‐1, where it is available. Aim T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e62125d06e400b322f7b1eb02711e26f
http://europepmc.org/articles/PMC5434950
http://europepmc.org/articles/PMC5434950
Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1*
Autor:
Veit Gülberg, Frederick Regenstein, Alice S. Bexon, Peter Teuber, Guadalupe Garcia-Tsao, Lorenzo Rossaro, Beate Appenrodt, Arun J. Sanyal, Samuel H. Sigal, Thomas D. Boyer
Publikováno v:
Liver Transplantation. 17:1328-1332
The development of hepatorenal syndrome type 1 (HRS1) is associated with a poor prognosis. Liver transplantation improves this prognosis, but the degree of the improvement is unclear. Most patients receive vasoconstrictors such as terlipressin before
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::faa4684b8c94180aa1b0813db80461da
https://doi.org/10.1002/lt.22395
https://doi.org/10.1002/lt.22395
Autor:
Thomas D, Boyer, Arun J, Sanyal, Guadalupe, Garcia-Tsao, Andres, Blei, Daniel, Carl, Alice S, Bexon, Peter, Teuber, B, Appenrodt
Publikováno v:
Journal of Hepatology. 55:315-321
Administration of terlipressin plus albumin is effective in reversing type 1 HRS as compared to albumin alone. However, only about 1/3 of patients respond to treatment, therefore, predictors of response and survival would help identify the patients m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::767c4e5f08d0d338c01ff9eef1829e56
https://doi.org/10.1016/j.jhep.2010.11.020
https://doi.org/10.1016/j.jhep.2010.11.020
Autor:
Peter Teuber, Thomas D. Boyer, Frederick Regenstein, Veit Gülberg, Andres T. Blei, Guadalupe Garcia-Tsao, Beate Appenrodt, Lorenzo Rossaro, Samuel H. Sigal, Arun J. Sanyal
Publikováno v:
Gastroenterology. 134:1360-1368
Background & Aims: Hepatorenal syndrome (HRS) type 1 is a progressive functional renal failure in subjects with advanced liver disease. The aim of this study was to evaluate the efficacy and safety of terlipressin, a systemic arterial vasoconstrictor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adeb93022938cc4d7fef03ed6e38b522
https://doi.org/10.1053/j.gastro.2008.02.014
https://doi.org/10.1053/j.gastro.2008.02.014
Publikováno v:
auto. 44:405-412
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::665730b2e1156420122e53d53fadbb0e
https://doi.org/10.1524/auto.1996.44.8.405
https://doi.org/10.1524/auto.1996.44.8.405
Autor:
Thomas D, Boyer, Arun J, Sanyal, Guadalupe, Garcia-Tsao, Frederick, Regenstein, Lorenzo, Rossaro, Beate, Appenrodt, Veit, Gülberg, Samuel, Sigal, Alice S, Bexon, Peter, Teuber, B, Appenrodt
Publikováno v:
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 17(11)
The development of hepatorenal syndrome type 1 (HRS1) is associated with a poor prognosis. Liver transplantation improves this prognosis, but the degree of the improvement is unclear. Most patients receive vasoconstrictors such as terlipressin before
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::2ae50a847d6130f6f9afd10a4dea7715
https://pubmed.ncbi.nlm.nih.gov/21932372
https://pubmed.ncbi.nlm.nih.gov/21932372